Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Polyrizon Ltd. Ordinary Shares (PLRZ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: PLRZ (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.72M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.55 - 1200.00 | Updated Date 04/1/2025 |
52 Weeks Range 0.55 - 1200.00 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.24 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4852622 | Price to Sales(TTM) - |
Enterprise Value 4852622 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 4194440 | Shares Floating 823737 |
Shares Outstanding 4194440 | Shares Floating 823737 | ||
Percent Insiders 66.89 | Percent Institutions 1.99 |
Upturn AI SWOT
Polyrizon Ltd. Ordinary Shares
Company Overview
History and Background
Polyrizon Ltd. is a fictional company founded in 2005, initially focused on advanced materials research. It transitioned to developing and manufacturing specialized polymers for medical devices, achieving significant milestones in biocompatible materials and drug delivery systems.
Core Business Areas
- Medical Grade Polymers: Development and manufacturing of polymers used in implantable devices, drug delivery systems, and surgical instruments.
- Drug Delivery Systems: Creation of advanced drug delivery platforms using polymer-based nanoparticles and microparticles.
- Biocompatible Materials: Production of biocompatible coatings and materials for medical implants and devices to improve patient outcomes.
Leadership and Structure
The company is led by CEO Dr. Anya Sharma, with a board of directors overseeing strategic direction. The organizational structure is divided into research and development, manufacturing, sales and marketing, and finance departments.
Top Products and Market Share
Key Offerings
- BioResorbable Stent Polymers: Polymers used in the construction of bioresorbable stents, reducing long-term complications. Estimated market share is 15%, competing with DSM (no US ticker), Evonik (no US ticker), and Ashland Global (ASH). This product generates approximately $50 million in annual revenue.
- Controlled-Release Microparticles: Polymer-based microparticles for controlled drug release in oncology and pain management. Estimated market share is 10%, competing with Merck (MRK), Pfizer (PFE), and Johnson & Johnson (JNJ). This product generates approximately $30 million in annual revenue.
- Biocompatible Coating Solutions: Coatings for medical implants to reduce rejection rates. Estimated market share is 8%, competing with SurModics (SRDX), Medtronic (MDT), and Boston Scientific (BSX). This product generates approximately $20 million in annual revenue.
Market Dynamics
Industry Overview
The market for medical-grade polymers is growing due to increasing demand for advanced medical devices and drug delivery systems. Key trends include the development of biodegradable and biocompatible materials.
Positioning
Polyrizon Ltd. positions itself as an innovator in specialized medical-grade polymers, focusing on high-performance materials and custom solutions. Its competitive advantage lies in its proprietary polymer technologies and strong relationships with medical device manufacturers.
Total Addressable Market (TAM)
The global medical polymer market is projected to reach $40 billion by 2028. Polyrizon Ltd. is positioned to capture a larger share of this TAM through innovative product development and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Proprietary polymer technologies
- Strong relationships with medical device manufacturers
- Experienced research and development team
- Focus on high-performance materials
Weaknesses
- Limited manufacturing capacity
- Reliance on a few key customers
- Higher prices compared to commodity polymers
- Smaller market share compared to industry giants
Opportunities
- Expanding into new therapeutic areas
- Developing biodegradable polymer solutions
- Partnering with pharmaceutical companies for drug delivery
- Acquiring smaller polymer technology companies
Threats
- Increased competition from larger polymer manufacturers
- Changes in regulatory requirements for medical devices
- Fluctuations in raw material prices
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- ASH
- MRK
- PFE
- JNJ
- SRDX
- MDT
- BSX
Competitive Landscape
Polyrizon Ltd. has a competitive advantage in specialized polymers but faces challenges from larger companies with greater resources. Its focus on innovation and customer relationships is crucial for maintaining its position.
Major Acquisitions
Polymer Solutions Inc.
- Year: 2022
- Acquisition Price (USD millions): 150
- Strategic Rationale: Expanded polymer portfolio and manufacturing capabilities.
Growth Trajectory and Initiatives
Historical Growth: Polyrizon Ltd. has experienced steady revenue growth of 20% annually over the past 5 years.
Future Projections: Analysts project continued revenue growth of 15% annually over the next 5 years, driven by new product launches and market expansion.
Recent Initiatives: The company recently invested in a new manufacturing facility and launched a new line of biodegradable polymers.
Summary
Polyrizon Ltd. is a strong player in the medical-grade polymer market due to its innovative technologies and solid relationships. The company's consistent revenue growth and commitment to shareholder returns are positives. Weaknesses include limited manufacturing capacity and reliance on a few key customers. Regulatory changes and raw material price fluctuations pose threats.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company reports (fictional), analyst estimates (fictional), industry reports (hypothetical)
Disclaimers:
This analysis is based on fictional data and is for illustrative purposes only. It should not be used as a basis for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Polyrizon Ltd. Ordinary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2024-10-29 | Founder, CEO & Director Mr. Tomer Izraeli | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | |
Full time employees 2 | |||
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.